Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Maffini

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Bone Marrow Transplantation|July 14, 2022
Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Myriam Labopin, Dietrich Wilhelm Beelen, et al.
Frontiers in Immunology|February 2, 2023
Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicitySerena De Matteis, Michele Dicataldo, Beatrice Casadei, et al.
Journal of Neurology|April 25, 2025
EEG as a predictive biomarker of neurotoxicity in anti-CD19 CAR T-cell therapyFederica Pondrelli, Lorenzo Muccioli, Federico Mason, et al.
Transplantation and Cellular Therapy|April 6, 2024
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction SyndromeMirko Farina, Maria Chiara Scaini, Antonella Facchinetti, et al.
Haematologica|December 20, 2024
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcomeSerena De Matteis, Laura Del Coco, Federica De Castro, et al.
Haematologica|April 23, 2026
Pre-treatment circulating microRNA signatures predict outcomes of anti-CD19 CAR T-cell therapyMaria Naddeo, Roberta Roncarati, Francesco De Felice, et al.
Transplantation Direct|February 27, 2023
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld StudyMichele Malagola, Nicola Polverelli, Massimo Martino, et al.
The Journal of Clinical Investigation|June 4, 2024
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cellsGianluca Storci, Francesco De Felice, Francesca Ricci, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Bone Marrow Transplantation|July 14, 2022
Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Myriam Labopin, Dietrich Wilhelm Beelen, et al.
Frontiers in Immunology|February 2, 2023
Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicitySerena De Matteis, Michele Dicataldo, Beatrice Casadei, et al.
Journal of Neurology|April 25, 2025
EEG as a predictive biomarker of neurotoxicity in anti-CD19 CAR T-cell therapyFederica Pondrelli, Lorenzo Muccioli, Federico Mason, et al.
Transplantation and Cellular Therapy|April 6, 2024
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction SyndromeMirko Farina, Maria Chiara Scaini, Antonella Facchinetti, et al.
Haematologica|December 20, 2024
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcomeSerena De Matteis, Laura Del Coco, Federica De Castro, et al.
Haematologica|April 23, 2026
Pre-treatment circulating microRNA signatures predict outcomes of anti-CD19 CAR T-cell therapyMaria Naddeo, Roberta Roncarati, Francesco De Felice, et al.
Transplantation Direct|February 27, 2023
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld StudyMichele Malagola, Nicola Polverelli, Massimo Martino, et al.
The Journal of Clinical Investigation|June 4, 2024
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cellsGianluca Storci, Francesco De Felice, Francesca Ricci, et al.
Pageof 4